Ginkgo Bioworks reportedly explores $20B SPAC deal
Synthetic biology company Ginkgo Bioworks is toying with the idea of going public via a reverse merger with special-purpose acquisition company Soaring Eagle Acquisition Corp.
The potential deal, first reported by Bloomberg, could value Ginkgo at more than $20 billion — more than five times what Ginkgo was valued at in late 2019, when it last raised venture capital.
Ginkgo Bioworks declined to comment.
The news comes as deals with special-purpose acquisition compani es, known as the number of…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Rowan Walrath Source Type: news
More News: Biology | Biotechnology | Ginkgo | Health Management | Mergers and Aquisitions | Venture Capital